KILITCHNSEKilitch Drugs (India) Limited· PharmaceuticalsHighNeutral
Announced Wed, 2 Jul · 13:03 IST

Raising of funds by way of issue of equity shares of the Company on right issue basis

Corporate Actions View source PDF

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Kilitch Drugs (India) Limited announced that its Board of Directors, at a meeting held on July 2, 2025, approved raising funds up to Rs. 50 crores through a Rights Issue of equity shares with a face value of Rs. 10 each. The proceeds will be used to fund capital expenditure for a Greenfield Project in Pen, Maharashtra, as well as for general corporate purposes and right issue-related expenses. The record date for identifying eligible shareholders will be notified separately, and detailed terms will be included in the Letter of Offer to be sent to eligible shareholders. The company has also sought in-principal approval for the rights issue under applicable SEBI regulations.

Likely market impact

The rights issue will dilute existing shareholders' stakes unless they fully participate. The fresh capital injection signals growth plans via the new Greenfield manufacturing facility, which could support long-term business expansion if the project delivers expected returns.